L&C BIO (290650) Q2 2026 earnings summary

Executive summary

• The company specializes in human tissue grafts, tissue-based medical devices, cosmeceuticals, and related CRO services, with a strong focus on R&D and global expansion.

• Major revenue drivers are human tissue grafts and medical devices, with expanding indications and international certifications.

• The company completed full acquisition of its Chinese subsidiary and continues to invest in R&D and production capacity.

Financial highlights

• Consolidated revenue for H1 2026 was KRW 69.1 billion, down from KRW 85.5 billion in FY2025.

• Operating income for H1 2026 was KRW 14.6 billion, compared to a loss of KRW 25.4 billion in FY2025.

• Net loss attributable to owners for H1 2026 was KRW -25.4 billion, improved from KRW -138.2 billion in FY2025.

• Basic EPS for H1 2026 was KRW -990, compared to KRW -5,810 in FY2025.

• Total assets at June 30, 2026: KRW 477.4 billion; equity: KRW 335.2 billion.

Outlook and guidance

• The company plans a rights offering and public share issue of 3.7 million shares to raise capital for operations, facilities, and debt repayment, with payment due October 22, 2026.

• Focus remains on expanding global market share, launching new products, and strengthening R&D pipeline.